DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vadimezan
Vadimezan
Co-Administration of Vadimezan and Recombinant Coagulase-NGR Inhibits Growth of Melanoma Tumor in Mice
DMXAA Causes Tumor Site-Specific Vascular Disruption
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy
Intratumoral STING Activation Sensitizes Poorly Immunogenic Cancers to Checkpoint Blockade Immunotherapy
Vascular Targeted Agents for the Treatment of Angiosarcoma
WO 2018/217651 Al 29 November 2018 (29.11.2018) W !P O PCT
STING Agonist Inflames the Pancreatic Cancer Immune Microenvironment and Reduces Tumor Burden in Mouse Models Weiqing Jing1†, Donna Mcallister2†, Emily P
Disrupting Tumour Vasculature and Recruitment of Apdl1-Loaded Platelets Control Tumour Metastasis
WO 2021/026099 A1 11 February 2021 (11.02.2021) W P O PCT
Discovery of Potential Therapeutic Targets for Non-Small Cell Lung
Prostate-Specific Antigen-Based Screening for Prostate Cancer: an Evidence Update for the U.S
Sponsor Novartis Generic Drug Name Vadimezan Therapeutic Area
Exploring Flavone-8-Acetic Acid and Derivatives in the New Century
An Overview on Vadimezan (DMXAA): the Vascular Disrupting Agent
Intratumoural Administration and Tumour Tissue Targeting of Cancer Immunotherapies
Anti-Cancer Potential of Tumor-Vascular Disrupting Agents
Top View